A cost-effectiveness analysis of sotorasib as second-line treatment for patients with KRAS-G12C-mutated metastatic non-small cell lung cancer (mNSCLC) in Switzerland by Tämer El Saadany, Judith Lupatsch, Michael Mark, Michaela Barbier, Tarun Mehra, Matthias Schwenkglenks, Roger von Moos

“… BACKGROUND AND OBJECTIVE: Because of the lack of effective targeted treatment options, docetaxel has long been the standard second-line therapy for patients with advanced non-small cell lung cancer, including the Kirsten rat sarcoma virus (KRAS) G12C mutation. …”
Get full text

Research progress of Traditional Chinese Medicine nursing techniques for cough symptoms of lung cancer patients (中医护理技术改善肺癌患者咳嗽症状的研究进展) by HOU Yanli (侯燕丽), ZHANG Ying (张英), LIN Haiqing (林海青), CHEN Mengna (陈梦娜), CHEN Yang (陈扬)

Subjects: “…lung cancer…”
Get full text

Can smoking duration alone replace pack-years to predict the risk of smoking-related oncogenic mutations in non-small cell lung cancer? A cross-sectional study in Japan by Masahiko Ando, Yoshihiko Taniguchi, Akihiro Tamiya, Akihide Matsumura, Koichi Ogawa, Yasuhiro Koh, Hiroyasu Kaneda, Motohiro Izumi, Yoshiya Matsumoto, Kenji Sawa, Mitsuru Fukui, Naoki Yoshimoto, Akihito Kubo, Shun-ichi Isa, Hideo Saka, Tomoya Kawaguchi

“…Objective To investigate whether smoking duration alone can replace pack-years to predict the risk of oncogenic mutations in non-small cell lung cancer (NSCLC).Design A cross-sectional study using the baseline dataset from the Japan Molecular Epidemiology for Lung Cancer Study.Setting Forty-three medical institutions nationwide in Japan.Participants From July 2012 to December 2013, 957 patients with newly diagnosed stage I–IIIB NSCLC who underwent surgery were enrolled, and molecular analyses were performed on 876 samples (from 441 ever-smokers and 435 never-smokers).Main outcomes measured We calculated the area under the receiver operating characteristic curve (AUC) values using logistic regression to compare between the predictive values of smoking duration and pack-years for mutational frequencies in the v-Ki-ras2 Kirsten rat sarcoma (KRAS), tumour suppressor p53 (TP53), and epidermal growth factor receptor (EGFR) genes and for cytosine-to-adenine base substitution (C>A).Results For predicting KRAS mutations, the AUC values for smoking duration and pack-years were 0.746 (95% CI 0.682 to 0.800) and 0.759 (95% CI 0.700 to 0.810), respectively (p=0.058). …”
Get full text

[18F]FDG PET/CT versus [18F]FDG PET/MRI in staging of non-small cell lung cancer: a head-to-head comparative meta-analysis by Dandan Yu, Chaolin Chen

Subjects: Get full text

Study on postoperative survival prediction model for non-small cell lung cancer: application of radiomics technology workflow based on multi-organ imaging features and various machine learning algorithms by Hanlin Wang, Yuan Hong, Zimo Zhang, Kang Cheng, Bo Chen, Renquan Zhang

“…ObjectiveThis study aims to construct an effective prediction model for the two-year postoperative survival probability of patients with non-small cell lung cancer (NSCLC). It particularly focuses on integrating radiomics features, including the erector spinae and whole-lung imaging features, to enhance the accuracy and stability of prognostic predictions.Materials and methodsThe study included 37 NSCLC patients diagnosed and surgically treated at the First Affiliated Hospital of Anhui Medical University from January 2020 to December 2021. …”
Get full text

Combined blockade of GPX4 and activated EGFR/HER3 bypass pathways inhibits the development of ALK‐inhibitor‐induced tolerant persister cells in ALK‐fusion‐positive lung cancer by Koh Furugaki, Takaaki Fujimura, Narumi Sakaguchi, Yasutaka Watanabe, Ken Uchibori, Eisaku Miyauchi, Hidetoshi Hayashi, Ryohei Katayama, Shigeki Yoshiura

“…We generated alectinib‐induced DTP cells from a patient‐derived ALK+ non‐small‐cell lung cancer (NSCLC) cell line and screened 3114 agents in the anticancer compounds library (TargetMol). …”
Get full text

PD-L1 and IFN-γ modulate Non-Small Cell Lung Cancer (NSCLC) cell plasticity associated to immune checkpoint inhibitor (ICI)-mediated hyperprogressive disease (HPD) by Stefania Angelicola, Francesca Giunchi, Francesca Ruzzi, Mariateresa Frascino, Mary Pitzalis, Laura Scalambra, Maria Sofia Semprini, Olga Maria Pittino, Chiara Cappello, Irene Siracusa, Ilaria Candida Chillico, Martina Di Noia, Cristian Turato, Silvia De Siervi, Francesco Lescai, Teresa Ciavattini, Giulia Lopatriello, Luca Bertoli, Hugo De Jonge, Luisa Iamele, Annalisa Altimari, Elisa Gruppioni, Andrea Ardizzoni, Marzia Rossato, Francesco Gelsomino, Pier-Luigi Lollini, Arianna Palladini

Subjects: “…Non-Small Cell Lung Cancer…”
Get full text

A Response Letter to Kosaka et al. Regarding Manuscript Titled: “Radiotherapy Improves Survival in Non–Small Cell Lung Cancer Following Oligoprogression on Immunotherapy: A Cohort Study” by Lauren Julia Brown, M.B.B.S., MClinTRes, FRACP, Julie Ahn, M.B.B.S., Bo Gao, BmedSci, M.B.B.S., FRACP, PhD, Harriet Gee, M.B.B.S., DPhil, FRANZCR, Adnan Nagrial, M.B.B.S., FRACP, PhD, Inês Pires da Silva, MD, FRACP, PhD, Eric Hau, BSc (Med), M.B.B.S., Grad Cert (Biostat), FRANZCR, PHD

Get full text

Association between forced expiratory volume in 1 s and relapse-free survival in operable non-small cell lung cancer: a prospective cohort study with propensity score overlap weighting by Jing Cheng, Yang Du, Karl Sylvester, Shaoping Wu, Suixin Liu, Yaoshan Dun, Baiyang You, Siqian Fu, Ning Xu, Jeffrey William Ripley-Gonzalez, Ni Cui

“…Objectives Investigate the correlation between the percentage of predicted forced expiratory volume in 1 s (FEV1%pred) and survival outcomes, namely relapse-free survival (RFS) and overall survival (OS), in patients diagnosed with operable early-stage non-small cell lung cancer (NSCLC).Design Prospective observational study.Setting Clinical settings in Xiangya Hospital, Central South University, Hunan, China.Participants From November 2014 to December 2019, 775 operable patients with NSCLC, median age 58 years (IQR 13) with 40.6% women, were consecutively enrolled and underwent preoperative FEV1 assessment. …”
Get full text

E3 Ubiquitin Ligase CHIP Inhibits the Interaction between Hsp90β and MAST1 to Repress Radiation Resistance in Non-Small-Cell Lung Cancer Stem Cells by Bo Tan, Jingwei Zhang, Wen Wang, Haibo Ma, Yuanyuan Yang

“…CD133+ cells were isolated from the NSCLC tissues and the lung cancer cell line A549 by flow cytometric sorting. …”
Get full text

A clinical efficacy analysis of single-port thoracoscopic lung resection in the treatment of male patients with non-small cell lung cancer using surface localization and CT-guided sclerosant by Qinghua Wang, Yujie He, Xiaowei Xie, Qinghua Wu

Subjects: Get full text

Considering Patients’ Mental Capacity When Giving Them Bad News May Help Their Well-Being: A Case of Suicide Attempt after Being Informed of Lung Cancer Diagnosis by Toshiyuki Kobayashi, Satoshi Kato, Mitsuo Takeuchi

“…To show the importance of this concept, a case of suicide attempt with lung cancer is exemplified. A 76-year-old woman attempted suicide after receiving a diagnosis of lung cancer. …”
Get full text

Retraction notice to “Engineering of dopamine conjugated with bovine serum albumin and zeolite imidazole framework: A promising drug delivery nanocarrier on lung cancer cells” [Heliyon 10 (2024) e36580] by Chenggang Lei, Di Liu, Qian Zhou, Shengwei Ma, Haiyun Qian

Get full text

Successful Treatment for Hypercalcemia due to Cosecretion of Parathyroid Hormone-Related Protein and 1,25-Dihydroxyvitamin D3 in Non-Small-Cell Lung Cancer: A Case Report and Literature Review by Takunori Ogawa, Jun Miyata, Koichi Fukunaga, Akihiko Kawana, Takashi Inoue

“…To our knowledge, this is the first case report on the successful treatment of hypercalcemia of malignancy caused by PTHrP and 1,25-dihydroxyvitamin D3 cosecretion in a patient with lung cancer.…”
Get full text

Updated Bayesian network meta-analysis on the efficacy and safety of PD−1 versus PD−L1 inhibitors in first−line treatment with chemotherapy for extensive−stage small-cell lung cancer by Ke Wang, Ke Wang, Chuangjie Zheng, Chuangjie Zheng, Xinrong Chen, Xinrong Chen, Penghui Lin, Mengge Lin, Cuizhen Chen, Linzhu Zhai

Subjects: “…extensive-stage small-cell lung cancer…”
Get full text

The miR-23a/27a/24 − 2 cluster drives immune evasion and resistance to PD-1/PD-L1 blockade in non-small cell lung cancer by Hao Luo, Bin Hu, Xiang-Rong Gu, Jing Chen, Xiao-Qing Fan, Wei Zhang, Ren-Tao Wang, Xian-Dong He, Wei Guo, Nan Dai, Dan Jian, Qing Li, Cheng-Xiong Xu, Hua Jin

“…Here, we demonstrated that the upregulation of all miRNAs in the miR-23a/27a/24 − 2 cluster was correlated with poor survival, immune evasion and PD-1/PD-L1 blockade resistance in patients with non-small cell lung cancer (NSCLC). The overexpression of all miRNAs in the miR-23a/27a/24 − 2 cluster upregulated PD-L1 expression by targeting Cbl proto-oncogene B (CBLB) and downregulated MHC-I expression by increasing the level of eukaryotic initiation factor 3B (eIF3B) via the targeting of microphthalmia-associated transcription factor (MITF). …”
Get full text

Real-world ePRO use and clinical outcomes using electronic patient-reported symptom monitoring for patients with advanced non-small-cell lung cancer receiving first-line pembrolizumab by L. Johnetta Blakely, Sabine Oskar, Ian Kudel, Ashley Roush, Zoya Shamsi, Toni Perry, Annette Christianson, Brittni Smith, Thomas Burke

Subjects:

A multicenter, randomized, double-blind, placebo-controlled phase 3 study of Socazolimab or placebo combined with carboplatin and etoposide in the first-line treatment of extensive-stage small cell lung cancer by Zhiwei Chen, Jianhua Chen, Dingzhi Huang, Wei Zhang, Lin Wu, Tienan Yi, Qiming Wang, Liang Han, Liping Tan, Yinyin Li, Zhihong Zhang, Na Li, Jie li, Tongmei Zhang, Ying Hu, Hongmei Sun, Youhua Wu, Zhiyong He, Runxiang Yang, Peng Cheng, Xingya Li, Jianhua Shi, Guohua Yu, Daiyuan Ma, Benjamin Xiaoyi Li, Xiangrong Dai, Michael Wong, Yujie Li, Xiaohui Yu, Shun Lu, for the Socazolimab Study Group

“…Adults who were histologically diagnosed and never treated for extensive-stage small cell lung cancer (ES-SCLC) were enrolled. Eligible Patients were randomly assigned (1:1) to receive four cycles (21 days as one cycle) of intravenous carboplatin (area under the curve of 5 mg/mL per min, day 1 of each cycle) and etoposide (100 mg/m² of body-surface area, on days 1–3 of each cycle) with either socazolimab (5 mg/kg, day 1 of each cycle) or matching placebo, following maintenance therapy with socazolimab or placebo. …”
Get full text

Intervening Non-Small-Cell Lung Cancer Progression by Cell Membrane Coated Platycodin D via Regulating Hsa-miR-1246/FUT9/GSK3β Pathway by Zheng S, Xie Z, Zhou Z, Wang S, Xin Y, Lin J, Cheng K, Lu T, Qi R, Guo Y

Subjects: “…non-small cell lung cancer…”
Get full text

Comparisons of adverse events associated with immune checkpoint inhibitors in the treatment of non-small cell lung cancer: a real-world disproportionality analysis based on the FDA adverse event reporting system by Ruichen Gao, Wenjun Liang, Jintao Chen, Mingxia Yang, Xiaowei Yu, Xiaohua Wang

Subjects: Get full text